Visible results seen in real-world patients

In DUPIXENT clinical trials including adults, the primary endpoint was the change from baseline in the proportion of subjects with an Investigator’s Global Assessment (IGA) of 0 (clear) or 1 (almost clear) and ≥2-point improvement at Week 16.1

Actual patients treated with DUPIXENT. Not clinical trial patients. Patients 2 and 3 were on concomitant therapies, such as TCS, phototherapy, etc, at their prescribing healthcare professional’s discretion. Scoring was designated by the treating healthcare professional. Because all 3 patients were real-world patients, there may be other factors influencing their treatment results, and individual results may vary.

Patient 1: achieved a 3-point improvement in IGA

DRAG TO SEE
RESULTS

Patient 2: achieved a 3-point improvement in IGA

DRAG TO SEE
RESULTS

Patient 3: achieved a 4-point improvement in IGA

DRAG TO SEE
RESULTS

A clinical responder was defined as a patient achieving IGA 0 or 1 and at least a 2-point improvement from baseline.1

Significantly clearer skin

18+ YEARS
Skin clearance at Week 16 (primary endpoint) and Week 52 (secondary endpoint) with DUPIXENT + TCS in CHRONOS2,3,a-e
CHRONOS: Concomitant Therapy With TCS

Definitive conclusions cannot be made at Week 4, as this was a post hoc analysis. Data was not multiplicity controlled and P value was nominal.

39%
of DUPIXENT + TCS adult patients achieved clear or almost-clear skin at Week 16 vs 12% with placebo
+ TCS (primary endpoint; P<0.0001)1,3

Significant skin clearance was also demonstrated with DUPIXENT in monotherapy trials1,4

38%
of adults treated with DUPIXENT (n=224) achieved clear or almost-clear skin (primary endpoint) vs 10%
with placebo at Week 16 in SOLO 1 (n=224; P<0.001)
36%
of adults treated with DUPIXENT (n=233) achieved clear or almost-clear skin (primary endpoint) vs 9%
with placebo at Week 16 in SOLO 2 (n=236; P<0.001)
VIEW ADULT STUDY DESIGNS

aA clinical responder was defined as a subject with IGA 0 or 1 (clear or almost clear) with a reduction of ≥2 points from baseline on a 0-4 IGA scale at Week 16 in all
trials (primary efficacy outcome) and at Week 52 in CHRONOS (other endpoint).1

bIn the primary analyses of the efficacy endpoints, subjects who received rescue treatment or with missing data were considered nonresponders.1

cFull Analysis Set includes all subjects randomized.1

dIn CHRONOS, as needed, subjects received topical calcineurin inhibitors for problem areas only, such as the face, neck, and intertriginous and genital areas.1

eWeek 52 data were limited to patients completing 52 weeks as of the cutoff date.2

EXPLORE MORE IGA
EFFICACY RESULTS

VIEW ADOLESCENT
(12 TO 17 YEARS) DATA VIEW INFANT TO PRESCHOOLER
(6 MONTHS TO 5 YEARS) DATA VIEW CHILD
(6 TO 11 YEARS) DATA VIEW AD PATIENTS (12+ years) WITH HAND AND/OR FOOT INVOLVEMENT DATA

IGA assesses the overall severity of the clinical signs of atopic dermatitis2

A 0- to 4-point scoring system of the overall severity of atopic dermatitis skin lesions2

4

Severe
Disease

Severe erythema and severe
papulation/infiltration

3

Moderate
Disease

Moderate erythema and moderate
papulation/infiltration

2

Mild
Disease

Mild erythema and mild
papulation/infiltration

1

Almost
Clear

Just perceptible erythema, and
just perceptible papulation/infiltration

0

Clear
 

No inflammatory signs of atopic
dermatitis

A clinical responder
was defined as a
patient achieving IGA 0 or 1 and at least a
2-point improvement
from baseline1

Dosage and administration

Thinking about prescribing DUPIXENT?
Find the information you need to get started.

Explore ADMINISTRATION Options